CompletedNCT00050206
Olanzapine for mania in adolescents with bipolarity
About this title
Read the official source — NCT00050206Medication studyAges 13–17United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
- Listed locations
- IndianapolisSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2002
- Recruitment status
- Completed
- Enrollment listed in the registry
- 130
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT00050206
- Official title
Show the full official title
Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Indianapolis
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
